OMF Introduces #OMFScienceWednesday

Introducing #OMFScienceWednesday! Every Wednesday, our Research Liaison Raeka Aiyar from Stanford University will post on Facebook about the science that OMF is supporting: background on key areas, updates on the latest research, explanations of topics relevant to ME/CFS… be sure to like our Facebook page so you don’t miss out!
To start with, what do we mean when we say ME/CFS is a molecular disease, and why is that helpful for research? Molecular biology involves DNA, RNA, metabolites, proteins, cytokines – and there is evidence that so many of these are involved in ME/CFS. Molecular biology presents new opportunities to study ME/CFS: this is the golden era of molecular technologies, like genomics and other ‘omics’ (transcriptomics, metabolomics, proteomics) that allow us to measure the full set of these molecules produced by the body, cheaply and effectively. These studies can help us to understand how the disease works – for example, which viruses may trigger it or whether genetics may increase your risk – and to identify molecular biomarkers that are clearly different in patients compared to healthy people, which may be useful in diagnosing ME/CFS. Finally, molecular biology will hopefully lead to new molecular treatments: knowing which molecules are out of balance could point to ways to treat ME/CFS.

A great example of this is the recent metabolomics study published by Dr. Bob Naviaux (http://www.pnas.org/content/113/37/E5472.long), in which he found several metabolites whose levels are different in ME/CFS patients. This metabolic ‘signature’ could be useful as a biomarker, and could help to understand the energy deficiency issues in the disease. OMF is supporting a metabolomics validation study to confirm and extend Dr. Naviaux’s findings, and a collaboration with Dr. Ron Davis’ group to use genome sequencing to understand how genetics may be influencing metabolism in ME/CFS.
Check our Facebook each Wednesday, search #OMFScienceWednesday, and visit our website.
#OMFScienceWednesday
Facebook
Twitter
WhatsApp
Email

Latest News

black square image with two white lines at the top and bottom of the image. Then another two white lines come out from the sides to the middle over the #MEAction logo and the words, #NotJustFatigue Video Series Elizabeth Ansell Interview.

#NotJustFatigue Video Series: Interview with Creator Elizabeth Ansell

Over the past year, the #NotJustFatigue website, created by Elizabeth Ansell, releases a 10-part, documentary style, short form video series on different aspects involved in living with ME. Titles of the videos include topics such as: You Have No Idea How Serious This Is, Nobody Believes ME, and It’s Not Hysteria: It’s Sexism. In these

Read More »
navy blue square. there are two white lines at the top and bottom of the square. The #MEAction logo in at the top of the image. The words #MEAction Georgia Voice of the Patient in coordination with the Center for Disease Control and Prevention & Emory School of Nursing.

#MEAction Georgia: Voice of the Patient in Coordination with CDC & Emory School on Nursing

Back in September, #MEAction Georgia State Chapter partnered with the Centers for Disease Control and Prevention (CDC) and Emory School of Nursing to host, Voice of the Patient: A Panel Discussion with #MEAction Georgia. This event was a continuation of #MEAction Georgia’s #MillionsMissing 2024: #TeachMETreatME programming. Erin Lee and Liz Burlingame of the #MEAction Georgia

Read More »
a light blue square image with medical instruments/tools as a border (pill bottles, scales, needles, covid protein spike, etc). At the top of the image is the Home Test to Treat Program logo, in blue font: Findings Summary. Below that the #MEAction logo and Body Politic Logo.

Home Test To Treat – Findings Summary

#MEAction and Body Politic collaborated last spring, with a new national telehealth program, Home Test to Treat. We are now able to share initial findings from the program! Here are some highlights: 80K + enrolled in the program across the country! 40K + test distributed 6K + individuals treated for COVID-19 or flu 5.6K+ organizations

Read More »
Scroll to Top